Epilepsy is one of the most common neurological diseases, affecting 70 million worldwide and up to 5 million people in
"moksha8 is committed to providing the highest quality products to physicians and patients to improve the treatment of critical CNS indications," said
"Eslicarbazepine acetate developed by BIAL is the outcome of BIAL's longstanding scientific commitment to CNS research and development and the desire to improve the quality of life in those patients with poor seizure control," commented
Eslicarbazepine acetate was approved by the
About epilepsy, partial-onset seizures and their treatment Epilepsy is a chronic neurological disease characterized by abnormal discharges of neuronal activity causing seizures. Clinically, these manifest as convulsions or jerking of muscles. Depending on the seizure type, seizures may be limited to one part of the body, or may be generalized to involve the whole body. Patients may also experience abnormal sensations, altered behaviour or altered consciousness. Epilepsy is a disorder with many possible causes. Often the cause of epilepsy is unknown. However, anything that disturbs the normal pattern of neuron activity - from illness to brain damage to abnormal brain development, can lead to seizures.
Epilepsy is characterised by abnormal firing of impulses from nerve cells in the brain. In partial-onset seizures, these bursts of electrical activity are initially focused in specific areas of the brain, but may become more generalised; the symptoms vary according to the affected areas. Nerve impulses are triggered via voltage-gated sodium channels in the nerve cell membrane.
Treatment of partial-onset seizures, the most common type of epilepsy, presents a constant challenge - up to 40% of patients with partial-onset seizures do not achieve sustained seizure control with current anti-epileptic drugs(1). Furthermore, central nervous system related adverse events, such as lightheadedness (dizziness), somnolence (sleepiness), and cognitive slowing (attention and memory deficits), are highly prevalent with existing anti-epileptic agents. Hence, there is a need for new anti-epileptic agents that offer effective reduction in seizure frequency combined with a favourable safety profile.
About eslicarbazepine acetate (Zebinix® / Exalief®) Eslicarbazepine acetate is a once-daily, voltage-gated sodium channel blocker. It preferentially targets the inactivated state of the ion channel, preventing its return to the active state, and thereby reduces repetitive neuronal firing (2-4).
Keywords for this news article include: Central Nervous System, Epilepsy, Marketing and Licensing Agreements, Neurologic Manifestations, Seizures, moksha8.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Study: Recessions Can Postpone Motherhood Forever
- Hispanic Entrepreneurs Short-changed in Texas
- Effort to Oust Assad Put on Hold
- Washington's 'The Equalizer' Debuts With $35 Million
- White House Intruder Got Farther Than Reported
- Los Angeles Set to Host Small Business Summit
- Hispanics Carry Big Clout: Census
- Qantas Puts World's Largest Plane on Longest Route
- Chicago Flight Delays: Questions Answered
- Jeb Bush: GOP Senate Would 'Fix a Few Things'